Acne vulgaris is the most common skin condition in the US, affecting up to 50 million
Americans. The American Academy of Dermatology (AAD) guidelines on acne treatment …

Purpose Acne vulgaris is a ubiquitous condition in men and women starting in adolescence.
It is often persistent and refractory to multiple treatment methods. Although multiple …

Methods: Patients with moderate-to-severe acne were randomized 1: 1 to twice-daily
treatment of the face with clascoterone or vehicle for 12 weeks (W); all patients continuing …

Background Two randomized phase 3 studies evaluated efficacy and safety of 1%
clascoterone cream, a topical androgen receptor inhibitor, in patients aged≥ 9 years with …

Many patients with acne remain unsatisfied with results from the various topical treatments
available and often do not improve, because of poor adherence. Even if topical …

Importance Acne is a common, multifactorial skin condition, and treatments with novel
mechanisms have been elusive. Objective To assess the safety and efficacy of clascoterone …

Objective: To review the efficacy and safety of clascoterone 1% cream for the treatment of
acne vulgaris in patients 12 years of age and older. Data Sources: A literature search …

Acne is a prevalent chronic inflammatory disease that can cause severe psychiatric effects
and physical scarring of the skin. Historically, although systemic antiandrogen acne …

Background Androgens foster acnegenic pathways. Objective To assess the long-term
safety of an androgen receptor inhibitor, clascoterone cream, 1%, in patients who …

Background Clascoterone cream 1% is approved for the treatment of acne vulgaris in
patients aged 12 years or older based on results from two identical pivotal Phase 3 trials …